• November 7, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today reported its financial results for the third quarter of 2019 and updated its guidance for full year 2019. The company reported revenue of $1.6 billion for the third quarter of 2019, an increase of 7% compared with the third quarter of 2018. Net income for the third quarter of 2019 was $433 million, or $0.90 per diluted share, an increase of 25% and 27%, respectively, on a reported basis. Adjusted net income1 for the thirdmore...
  • October 31, 2019
    PARSIPPANY, N.J. & MUKILTEO, Wash.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced the completion of the acquisition of Phoenix Central Laboratory for Veterinarians, Inc. (Phoenix Lab), a full service veterinary reference laboratory company, after fulfilling all closing requirements. With the addition of reference laboratory services, Zoetis now can provide more comprehensive diagnostics products and services as an enhanced value to veterinarians in the U.S. Financial terms of themore...
  • October 28, 2019
    COLLEGE STATION, TEXAS, AND PARSIPPANY, NEW JERSEY, October 28, 2019 -- Zoetis, the world's leading animal health company, has signed an agreement with Texas A&M University’s Health Science Center for Innovation in Advanced Development and Manufacturing (CIADM) to establish a facility for accelerating the development of transboundary and emerging disease vaccines -- including those for Foot-and-Mouth Disease (FMD), a virus that can cause serious illness in cattle, pigs, and sheep. Workingmore...
  • October 22, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE:ZTS) will participate in the Credit Suisse 28th Annual Healthcare Conference on Tuesday, Nov. 12, 2019, in Scottsdale, Ariz. Kristin Peck, CEO-elect, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, and Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. They are scheduled to present at 3:15 p.m. ET (1:15 p.m.more...
  • October 3, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a fourth quarter 2019 dividend payable to holders of the company’s common stock of $0.164 per share. The dividend is to be paid on Monday, Dec. 2, 2019, to holders of record on Tuesday, Oct. 22, 2019. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetismore...
  • October 3, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced that Kristin Peck will succeed Juan Ramón Alaix as Chief Executive Officer, effective January 1, 2020, and join the Board of Directors, effective immediately. Alaix, who has been CEO of Zoetis since its formation in 2012, has decided to retire as CEO effective December 31, 2019. He will act as an advisor on the leadership transition through December 31, 2020. Peck currently serves as Executive Vice President andmore...
  • September 30, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 7, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review third quarter 2019 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-more...
  • September 24, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE: ZTS) today announced that it has been named one of Working Mother magazine’s "100 Best Companies for Working Mothers" for the sixth consecutive year. The publication selects the top 100 companies in the U.S. that lead in areas of female representation and advancement, benefits, parental leave, childcare and flexible work arrangements. “We are honored to be building a legacy as a consistent member of Working Mother magazine’s topmore...
  • September 20, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted marketing authorisation for Simparica Trio™ (sarolaner/moxidectin/pyrantel) chewable tablets, a once-monthly triple combination antiparasitic medication for dogs with, or at risk from, mixed external and internal parasitic infestations. The granting of the marketing authorisation follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use on Julymore...
  • September 9, 2019
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that its scientists presented positive efficacy data for the company’s investigational, triple combination parasiticide product at the 2019 Triennial meeting of the American Heartworm Society (AHS) in New Orleans, La. Zoetis is developing a triple combination product containing sarolaner, moxidectin and pyrantel that is administered orally once a month as a preventative for heartworm disease and to treat and control ticks, fleas,more...